Caprolactam Chemicals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 18, 2025, 7:56 pm

Competitors of Caprolactam Chemicals Ltd

All Competitor Stocks of Caprolactam Chemicals Ltd

Quarterly Result

Last Updated: May 31, 2025, 6:36 am

Below is a detailed analysis of the quarterly data for Caprolactam Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 1.61 Cr.. The value appears to be declining and may need further review. It has decreased from 2.29 Cr. (Dec 2024) to 1.61 Cr., marking a decrease of 0.68 Cr..
• For Expenses, as of Mar 2025, the value is 1.38 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.82 Cr. (Dec 2024) to 1.38 Cr., marking a decrease of 0.44 Cr..
• For Operating Profit, as of Mar 2025, the value is 0.23 Cr.. The value appears to be declining and may need further review. It has decreased from 0.47 Cr. (Dec 2024) to 0.23 Cr., marking a decrease of 0.24 Cr..
• For OPM %, as of Mar 2025, the value is 14.29%. The value appears to be declining and may need further review. It has decreased from 20.52% (Dec 2024) to 14.29%, marking a decrease of 6.23%.
• For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.01 Cr. (Dec 2024) to 0.00 Cr., marking a decrease of 0.01 Cr..
• For Interest, as of Mar 2025, the value is 0.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.17 Cr. (Dec 2024) to 0.18 Cr., marking an increase of 0.01 Cr..
• For Depreciation, as of Mar 2025, the value is 0.41 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.40 Cr. (Dec 2024) to 0.41 Cr., marking an increase of 0.01 Cr..
• For Profit before tax, as of Mar 2025, the value is -0.36 Cr.. The value appears to be declining and may need further review. It has decreased from -0.09 Cr. (Dec 2024) to -0.36 Cr., marking a decrease of 0.27 Cr..
• For Tax %, as of Mar 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from -66.67% (Dec 2024) to 25.00%, marking an increase of 91.67%.
• For Net Profit, as of Mar 2025, the value is -0.45 Cr.. The value appears to be declining and may need further review. It has decreased from -0.03 Cr. (Dec 2024) to -0.45 Cr., marking a decrease of 0.42 Cr..
• For EPS in Rs, as of Mar 2025, the value is -0.98. The value appears to be declining and may need further review. It has decreased from -0.07 (Dec 2024) to -0.98, marking a decrease of 0.91.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 3:42 am

Growth

Last Updated: September 5, 2025, 2:51 pm

Balance Sheet

Last Updated: September 10, 2025, 3:18 pm

Below is a detailed analysis of the balance sheet data for Caprolactam Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 4.60 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.60 Cr..
• For Reserves, as of Mar 2025, the value is 0.23 Cr.. The value appears to be declining and may need further review. It has decreased from 0.95 Cr. (Mar 2024) to 0.23 Cr., marking a decrease of 0.72 Cr..
• For Borrowings, as of Mar 2025, the value is 8.72 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 5.86 Cr. (Mar 2024) to 8.72 Cr., marking an increase of 2.86 Cr..
• For Other Liabilities, as of Mar 2025, the value is 0.74 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.25 Cr. (Mar 2024) to 0.74 Cr., marking an increase of 0.49 Cr..
• For Total Liabilities, as of Mar 2025, the value is 14.29 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.66 Cr. (Mar 2024) to 14.29 Cr., marking an increase of 2.63 Cr..
• For Fixed Assets, as of Mar 2025, the value is 10.31 Cr.. The value appears strong and on an upward trend. It has increased from 10.29 Cr. (Mar 2024) to 10.31 Cr., marking an increase of 0.02 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 3.98 Cr.. The value appears strong and on an upward trend. It has increased from 1.37 Cr. (Mar 2024) to 3.98 Cr., marking an increase of 2.61 Cr..
• For Total Assets, as of Mar 2025, the value is 14.29 Cr.. The value appears strong and on an upward trend. It has increased from 11.66 Cr. (Mar 2024) to 14.29 Cr., marking an increase of 2.63 Cr..

However, the Borrowings (8.72 Cr.) are higher than the Reserves (0.23 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Caprolactam Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -1.54. This value is below the healthy minimum of 5. It has decreased from 0.43 (Mar 24) to -1.54, marking a decrease of 1.97.
• For Diluted EPS (Rs.), as of Mar 25, the value is -1.54. This value is below the healthy minimum of 5. It has decreased from 0.43 (Mar 24) to -1.54, marking a decrease of 1.97.
• For Cash EPS (Rs.), as of Mar 25, the value is 1.91. This value is below the healthy minimum of 3. It has decreased from 3.87 (Mar 24) to 1.91, marking a decrease of 1.96.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.50. It has decreased from 12.06 (Mar 24) to 10.50, marking a decrease of 1.56.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.50. It has decreased from 12.06 (Mar 24) to 10.50, marking a decrease of 1.56.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 14.65. It has decreased from 15.12 (Mar 24) to 14.65, marking a decrease of 0.47.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 3.33. This value is within the healthy range. It has decreased from 5.11 (Mar 24) to 3.33, marking a decrease of 1.78.
• For PBIT / Share (Rs.), as of Mar 25, the value is -0.11. This value is below the healthy minimum of 0. It has decreased from 1.67 (Mar 24) to -0.11, marking a decrease of 1.78.
• For PBT / Share (Rs.), as of Mar 25, the value is -1.49. This value is below the healthy minimum of 0. It has decreased from 0.59 (Mar 24) to -1.49, marking a decrease of 2.08.
• For Net Profit / Share (Rs.), as of Mar 25, the value is -1.54. This value is below the healthy minimum of 2. It has decreased from 0.42 (Mar 24) to -1.54, marking a decrease of 1.96.
• For PBDIT Margin (%), as of Mar 25, the value is 22.75. This value is within the healthy range. It has decreased from 33.81 (Mar 24) to 22.75, marking a decrease of 11.06.
• For PBIT Margin (%), as of Mar 25, the value is -0.81. This value is below the healthy minimum of 10. It has decreased from 11.07 (Mar 24) to -0.81, marking a decrease of 11.88.
• For PBT Margin (%), as of Mar 25, the value is -10.14. This value is below the healthy minimum of 10. It has decreased from 3.91 (Mar 24) to -10.14, marking a decrease of 14.05.
• For Net Profit Margin (%), as of Mar 25, the value is -10.51. This value is below the healthy minimum of 5. It has decreased from 2.83 (Mar 24) to -10.51, marking a decrease of 13.34.
• For Return on Networth / Equity (%), as of Mar 25, the value is -14.67. This value is below the healthy minimum of 15. It has decreased from 3.55 (Mar 24) to -14.67, marking a decrease of 18.22.
• For Return on Capital Employeed (%), as of Mar 25, the value is -1.12. This value is below the healthy minimum of 10. It has decreased from 10.62 (Mar 24) to -1.12, marking a decrease of 11.74.
• For Return On Assets (%), as of Mar 25, the value is -4.96. This value is below the healthy minimum of 5. It has decreased from 1.69 (Mar 24) to -4.96, marking a decrease of 6.65.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.29 (Mar 24) to 0.00, marking a decrease of 0.29.
• For Total Debt / Equity (X), as of Mar 25, the value is 1.80. This value exceeds the healthy maximum of 1. It has increased from 1.06 (Mar 24) to 1.80, marking an increase of 0.74.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.51. It has decreased from 0.60 (Mar 24) to 0.51, marking a decrease of 0.09.
• For Current Ratio (X), as of Mar 25, the value is 0.38. This value is below the healthy minimum of 1.5. It has increased from 0.24 (Mar 24) to 0.38, marking an increase of 0.14.
• For Quick Ratio (X), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 1. It has increased from 0.22 (Mar 24) to 0.34, marking an increase of 0.12.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 28.47. This value exceeds the healthy maximum of 8. It has increased from 6.31 (Mar 24) to 28.47, marking an increase of 22.16.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 2.44. This value is below the healthy minimum of 3. It has decreased from 4.73 (Mar 24) to 2.44, marking a decrease of 2.29.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.12. This value is below the healthy minimum of 3. It has decreased from 1.40 (Mar 24) to -0.12, marking a decrease of 1.52.
• For Enterprise Value (Cr.), as of Mar 25, the value is 28.94. It has decreased from 29.47 (Mar 24) to 28.94, marking a decrease of 0.53.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.29. This value exceeds the healthy maximum of 3. It has increased from 4.24 (Mar 24) to 4.29, marking an increase of 0.05.
• For EV / EBITDA (X), as of Mar 25, the value is 18.88. This value exceeds the healthy maximum of 15. It has increased from 12.53 (Mar 24) to 18.88, marking an increase of 6.35.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has decreased from 3.40 (Mar 24) to 3.01, marking a decrease of 0.39.
• For Price / BV (X), as of Mar 25, the value is 4.21. This value exceeds the healthy maximum of 3. It has decreased from 4.27 (Mar 24) to 4.21, marking a decrease of 0.06.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has decreased from 3.41 (Mar 24) to 3.01, marking a decrease of 0.40.
• For EarningsYield, as of Mar 25, the value is -0.03. This value is below the healthy minimum of 5. It has decreased from 0.01 (Mar 24) to -0.03, marking a decrease of 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness